Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Payables (2016 - 2025)

Standard Biotools (LAB) has disclosed Payables for 16 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Payables rose 7.09% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, up 7.09% year-over-year, with the annual reading at $5.4 million for FY2025, 7.09% up from the prior year.
  • Payables for Q4 2025 was $5.4 million at Standard Biotools, down from $6.6 million in the prior quarter.
  • The five-year high for Payables was $13.1 million in Q1 2024, with the low at $5.0 million in Q4 2024.
  • Average Payables over 5 years is $9.3 million, with a median of $9.3 million recorded in 2022.
  • The sharpest move saw Payables tumbled 51.19% in 2023, then surged 115.11% in 2024.
  • Over 5 years, Payables stood at $10.6 million in 2021, then fell by 25.35% to $7.9 million in 2022, then grew by 16.7% to $9.2 million in 2023, then plummeted by 45.33% to $5.0 million in 2024, then rose by 7.09% to $5.4 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $5.4 million, $6.6 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.